Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Sulfametopyrazine prophylaxis in chronic bronchitis.

D Davies, C S Darke

    British Journal of Diseases of the Chest
    |July 1, 1978
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Wildfire-related smoke inhalation worsens cardiovascular risk in sleep disrupted rats.

    Frontiers in environmental health·2023
    Same author

    A checklist of larval Digenea (Platyhelminthes: Trematoda) in molluscs from inland waters of Argentina: one hundred years of research.

    Journal of helminthology·2022
    Same author

    Influence of environmental variability and Emiliania huxleyi ecotypes on alkenone-derived temperature reconstructions in the subantarctic Southern Ocean.

    The Science of the total environment·2021
    Same author

    Optical pupillometry in traumatic brain injury: neurological pupil index and its relationship with intracranial pressure through significant event analysis.

    Brain injury·2019
    Same author

    In our opinion.

    British dental journal·2017
    Same author

    High-dose chemotherapy and autologous stem cell transplantation for primary central nervous system lymphoma: a multi-centre retrospective analysis from the United Kingdom.

    Bone marrow transplantation·2017

    Sulfametopyrazine, taken weekly for chronic bronchitis, halved respiratory illnesses and work absence. However, it did not improve individual illness duration or sputum characteristics, with minimal side effects.

    Area of Science:

    • Respiratory Medicine
    • Clinical Pharmacology

    Background:

    • Chronic bronchitis is a prevalent respiratory condition associated with significant morbidity and work-related disability.
    • Effective prophylactic treatments for chronic bronchitis are crucial for improving patient outcomes and reducing healthcare burdens.

    Purpose of the Study:

    • To evaluate the efficacy of weekly sulfametopyrazine in reducing the incidence of respiratory illnesses and associated work absence in patients with chronic bronchitis.
    • To assess the impact of sulfametopyrazine on illness duration, sputum characteristics, and the occurrence of side effects.

    Main Methods:

    • A double-blind, randomized controlled trial involving 218 patients diagnosed with chronic bronchitis.
    • Participants were managed by 32 general practitioners over one winter season.

    Related Experiment Videos

  • Treatment involved weekly administration of sulfametopyrazine compared to a placebo control group.

    • Main Results:

    • Weekly sulfametopyrazine significantly reduced the overall number of respiratory illnesses by approximately 50%.
    • Work time lost due to illness was also reduced by about half in the treatment group compared to controls.
    • No significant differences were observed in the duration of individual illness episodes, sputum amount, or sputum purulence.
    • Reported side effects were infrequent and mild.

    Conclusions:

    • Once-weekly sulfametopyrazine demonstrates a beneficial effect in reducing the frequency of respiratory illnesses and work absenteeism in chronic bronchitis patients.
    • The treatment does not appear to influence the severity or duration of individual exacerbations or sputum parameters.
    • Sulfametopyrazine is a well-tolerated option for managing chronic bronchitis with a favorable safety profile.